Description
Envarsus (Tacrolimus) Tablets with Prolonged Release 4 mg. №30
Composition:
Each tablet contains 4 mg of tacrolimus.
Mechanism of Action:
Tacrolimus, the active ingredient in Envarsus tablets, is a calcineurin inhibitor that suppresses the body’s immune response by inhibiting T-lymphocyte activation. This mechanism helps prevent organ rejection in transplant patients.
Pharmacological Properties:
Envarsus tablets with prolonged release ensure a controlled and sustained release of tacrolimus in the body, maintaining therapeutic drug levels for an extended period. This formulation reduces the need for frequent dosing and minimizes fluctuations in drug concentration.
Indications for Use:
Envarsus tablets are indicated for the prophylaxis of organ rejection in adult kidney or liver transplant patients. The extended-release formulation offers a convenient dosing option for long-term immunosuppression.
Contraindications:
Avoid using Envarsus if you have a known hypersensitivity to tacrolimus or any components of the tablet formulation. Consult with your healthcare provider for suitable alternative treatment options.
Side Effects:
Common side effects of Envarsus may include tremors, headache, hypertension, and gastrointestinal disturbances. Monitoring for potential adverse reactions is essential during treatment. Notify your healthcare provider promptly if you experience any concerning symptoms.
Usage Instructions:
Follow your healthcare provider’s prescribed dosage of Envarsus meticulously. Swallow the tablet whole with a full glass of water. Refrain from crushing, chewing, or breaking the tablet to ensure proper drug delivery.
Benefits Compared to Analogues:
Envarsus offers improved bioavailability and a consistent drug release profile compared to immediate-release tacrolimus formulations. Clinical studies have demonstrated the efficacy and safety of Envarsus in maintaining stable immunosuppression, enhancing patient adherence and long-term transplant outcomes.
Suitable Patient Groups:
Envarsus is suitable for adult transplant recipients requiring long-term immunosuppressive therapy. Dosage adjustments may be necessary based on individual patient factors. Consultation with a healthcare provider is crucial for personalized treatment planning.
Storage and Shelf Life:
Store Envarsus tablets at the recommended temperature and in a dry place. Check the expiration date on the packaging and avoid using expired medication. Proper storage conditions help maintain the stability and efficacy of the product.
Packaging Description:
Envarsus tablets are typically packaged in blister packs to ensure individual tablet integrity and protection from environmental factors. The packaging should include relevant product information, dosage instructions, and expiry details for patient reference.
Clinical Evidence and Proven Effectiveness:
Studies have shown that Envarsus (tacrolimus) with prolonged release effectively prevents organ rejection in transplant patients. The extended-release formulation provides consistent drug levels, reducing dosing frequency and improving patient compliance with therapy. Clinical trials have confirmed the efficacy and safety of Envarsus in maintaining stable immunosuppression, leading to favorable long-term outcomes in transplant recipients.
